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Abstract
Background: The prevalence of major depression (MD) according to population studies is the same for old
(65 years and older) and younger adults. In contrast, an elevated proportion of old MD patients are hospitalized
compared to younger adults with MD, indicating a need to expand the characteristics of old inpatients with MD.
To illustrate this point, the association between inflammation and MD in old psychiatric inpatients is sparsely
investigated even though an association between inflammation and treatment resistance among younger adults
with MD has been reported. In this study, we aimed to explore the plasma concentrations of 27 immune markers in old
inpatients with MD, and our purpose was to expand the understanding of inflammatory mechanisms in these patients.
Methods: Prior to electroconvulsive treatment of MD, we compared 64 inpatients with unipolar MD
(mean age 75.2 years) and 18 non-depressed controls (mean age 78.0 years). Symptoms characterizing
MD were assessed by the Hamilton Rating Scale of Depression (HRSD)-17, and the immune markers from
peripheral blood plasma were analysed using multiplex assay technology. For statistical analysis of data,
we used the independent samples median test, independent samples t-test, χ2-test, receiver operating
characteristic curve analyses, stepwise discriminant analysis, and multivariate linear regression.
Results: Twenty-two immune markers representing pro- and anti-inflammatory, adaptive and trophic
signalling had higher concentrations in the inpatients compared to the controls. Only the four immune
markers IL-1β, IL-5, IL-10 and IL-15 had concentrations below the lower detection limit in a considerable
portion (above 20%) of the patient cases. A combination of the concentration in plasma of TNF, vascular
endothelial growth factor (VEGF), IL-1β, IL-7 and monocyte chemotactic protein (MCP)-1, correctly classified
98.4% of the depressed patients and 83.3% of the non-depressed controls. Plasma concentration of TNF
and VEGF were associated with the HRSD-17 scores (p = 0.017 and 0.005, respectively).
Conclusions: Our results indicate that several inflammatory mechanisms may be highly activated in old
psychiatric inpatients with MD, and indicate that immune markers may contribute to a more comprehensive
understanding of MD in old persons.
Trial registration: NCT01559324 ClinicalTrials.gov.
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Background
According to population studies the prevalence of major
depression (MD) in old adults (65 years and older) is
reported to be about two to 5 % in the USA, Germany
and Norway [1–3]. Similarly, the prevalence of MD in
the general population, including young and old adults,
is reported to be three to 5 % in Western Europe and
Northern America [4]. Contrasting the stable prevalence
of MD over time, the proportion of MD among psychi-
atric inpatients increases seven fold from below 30 years
of age to age 70 and approaches 40% [5]. Consequently,
departments of geriatric psychiatry in Norway dispose
about one bed per 1000 aged 65 years and above, and
non-responders to psychotherapy and anti-depressive
medication treated in the primary health care are re-
ferred [6]. Thus, a better understanding of mechanisms
involved in treatment resistant MD in old age may con-
tribute to improve the quality of life and reduce the
health care costs. As inflammation is associated with
treatment resistance in younger adult patients with MD
[7], exploring immune markers in old psychiatric inpa-
tients with MD may contribute to expand the under-
standing of mechanisms that are involved.
The association between inflammation and MD in old
psychiatric inpatients is sparsely examined. One study re-
ported a 171% higher mean plasma level of interleukin
(IL)-1β in 19 old inpatients compared to 21 non-depressed
old controls [8]. In contrast, another study reported equal
plasma concentration of IL-1β, IL-6 and tumour necrosis
factor (TNF) between ten old MD psychiatric inpatients
and ten non-depressed nursing home residents [9]. Add-
itionally, several population-based, cross-sectional studies
support an association between IL-6 and MD in old people
[10–13] but the difference in plasma level of IL-6 between
the non-depressed and those with depressed mood seems
modest [12]. Accordingly, a meta-analysis including mainly
young adults found a medium effect size relationship
between MD and the markers IL-1 and IL-6, but sug-
gested a dose-response relationship between MD and
inflammation [14].
Ageing is associated with increased inflammation [15]
and together with age related cerebral hypo-perfusion
inflammation is hypothesized to be involved in develop-
ment of depression in old adults [16]. Accordingly, sero-
tonin receptor 2B (Htr2b) is reported to be upregulated
during ageing in rodents [17] and Htr2b is reported to
be co-localized with astrocytes and activated phagocytic
microglia in peri-infarcted brain areas in humans [17].
The Astrocyte is the crucial microglia in the homeo-
stasis of the human brain [18] and activated human
astrocytes release cytokines initiating monocyte trans-
migration [19]. Thus, a connection between inflam-
mation, microglia and mood regulation is suggested
[20] and an understanding of these mechanisms may
reveal useful biomarkers and new targets in treatment
of MD in the old [20].
In our study, we decided to explore the plasma con-
centrations of 27 immune markers in old psychiatric
inpatients with unipolar MD, because the association
between inflammation and MD is sparsely investigated
in old inpatients.
Methods
The aims of the study
In this study, we aimed to explore the plasma concentra-
tions of 27 immune markers in old psychiatric inpatients
with unipolar MD resistant to antidepressant treatment
compared to a group of non-depressed old persons.
Next, we aimed to ascertain whether a selection of
plasma immune markers simultaneously might classify
the depressed patients and the non-depressed controls.
Finally, we aimed to explore the association between
immune markers and the severity of symptoms charac-
terizing MD in old persons.
Study design
The current study is a pre-electroconvulsive treatment,
exploratory study comparing old psychiatric inpatients
diagnosed with unipolar MD to a non-depressed control
group of old persons. The study includes a subgroup of
the patients from a larger randomized controlled trial
[21], registered with the identifier: NCT01559324 at the
online clinical database ClinicalTrials.gov.
Inclusion criteria
To be included, the patients were required to fulfil the
criteria of the Diagnostic and Statistical Manual of Men-
tal Disorders, Text Revision (DSM IV-TR) [22] of having
a current episode of unipolar MD and having a score of
at least 18 on the 17-item Hamilton Rating Scale for
Depression (HRSD)-17 [23, 24]. The patient had to be
between 60 to 85 years of age and had to be competent
to give informed consent. All the patients were referred
for electroconvulsive therapy (ECT).
Exclusion criteria
The following were exclusion criteria; bipolar depressive
disorder, Parkinson’s disease, schizophrenia, schizoaffec-
tive disorder, alcohol or substance abuse during the last
three weeks, Mini Mental State Examination (MMSE)
[25, 26] score of < 24 or having a diagnosis of dementia.
Patients with medical conditions contradicting ECT, in-
cluding all acute medical conditions and life threatening
medical conditions including an advanced stage of can-
cer, were excluded. Likewise, patients having received
ECT within the previous six months were excluded.
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Patients recruited
We recruited Norwegian-speaking patients at the
Diakonhjemmet Hospital, Department of Geriatric
Psychiatry, a public hospital of Oslo, Norway. The
department serves approximately 28,000 inhabitants aged
65 years and older. The patients were recruited during the
period 1 September 2009 to 1 May 2013. Figure 1 depicts
the flowchart of the recruitment process for the patients
and controls. Ninety-seven patients were assessed for eli-
gibility and 64 patients were included in the trial. Among
the 33 excluded patients, 23 met exclusion criteria; two
did not meet inclusion criteria; six withdrew their consent
and two had their diagnosis altered.
Diagnostic procedure
Unipolar MD was diagnosed according to the DSM-IV-TR
criteria [22]. Screening for psychiatric co-morbidity was
performed by a consensus between two independent senior
consultants in geriatric psychiatry after a standardized
clinical interview including the diagnostic structural tool
Mini-international Neuropsychiatric Interview (specifically
the MINI-Plus) [27, 28]. The HRSD-17 was used to rate
the severity of the symptoms characterizing MD.
Physical examination
All included patients underwent a routine physical exam-
ination with special attention to the cardiac-, respiratory-
and nervous systems as a preparation for anaesthesia. The
physical examination also included assessment for body
mass index (BMI), blood sedimentation reaction (SR),
C-reactive protein (CRP), leukocytes, haemoglobin, elec-
trolytes, creatinine, liver-enzymes, thyroxine, HbA1c and
glucose. Present and previous physical diseases affecting
the immune system activity (e.g., cancer, inflammatory
diseases and infections) were registered. We measured the
cumulative medical burden of physical diseases using the
Cumulative Illness Rating Scale for Geriatric Patients
(CIRS-G) [29] (Table 1). One item regarding psychiatric
disorders was excluded from the CIRS-G. The use of
prescribed drugs was registered.
Control group
We recruited 20 non-depressed Norwegian speaking old
adults from a community senior citizens centre as a con-
trol group (Table 1). Two of the controls were excluded
because they had an advanced stage of cancer. This
exclusion criterion also applied to the patient group.
Symptoms of depression were assessed by the HRSD-17
(Table 1). We measured the cumulative medical burden
of physical diseases using the CIRS-G (Table 1) from
which the psychiatric item was excluded. Apart from
assessing BMI, we did not perform physical examina-
tions, and we did not register the use of psychotropic
drugs in the controls.
Blood sampling
EDTA-plasma in peripheral blood was collected be-
tween 08.00 and 10.00 a. m. from the patients and
between 10.00 and 11.00 a. m. from the controls. The
blood was collected from patients before interventions
with ECT. The blood was immediately centrifuged at
4 °C at 3000 x g for 15 min and immediately stored
in a local bio-bank at − 80 °C.
Laboratory analysis
The plasma samples were analysed (in a hospital la-
boratory in Bodø, Norway) using a multiplex cytokine
assay (Bio-Plex Human Cytokine 27-Plex Panel; Bio-Rad
Fig. 1 Flowchart recruitment of participants
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Laboratories Inc., Hercules, CA, USA) containing the fol-
lowing immune markers: IL-1β, IL-1 receptor antagonist
(ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12
(p70), IL-13, IL-15, IL-17, eotaxin, basic fibroblast growth
factor (bFGF), granulocyte-colony stimulating factor
(G-CSF), granulocyte macrophage colony stimulating fac-
tor (GM-CSF), interferon (IFN)-γ, interferon-inducible
protein (IP)-10, monocyte chemotactic protein (MCP)-1,
macrophage inflammatory protein (MIP)-1α, MIP-1β,
platelet derived growth factor (PDGF)-BB, regulated upon
activation T cell expressed and secreted (RANTES),
tumour necrosis factor (TNF)-α and vascular endothelial
growth factor (VEGF) (Table 3). The samples were ana-
lysed on a Multiplex Analyzer (Bio-Rad Laboratories)
according to instructions from the manufacturer. The
lower detection limit was in the range of 0.24–
18.84 pg/ml for the different immune markers. Values
measured below the lower detection limit were extrapo-
lated beyond standard range and values out of range
were given the value 0.001 pg/ml in the statistical analysis.
We classified the immune markers in the categories; pro-
and anti-inflammatory, adaptive [30] and trophic based on
their main signalling (Table 2).
Statistical analysis
The demographic and clinical characteristics were pre-
sented as group means and standard deviations (SDs) or
frequencies and percentages. We compared group charac-
teristics of patients and controls, as well as patients with
and without physical diseases affecting the immune sys-
tem activity, using independent samples t-test and χ2-test.
The immune markers were non-normally distributed, and
therefore we described them using medians and first and
third quartiles. We conducted group comparisons be-
tween the patients with and without physical diseases af-
fecting the immune system activity as well as between the
patients and the controls using the independent samples
median test. As the distribution of most immune markers
was highly skewed, we used the LN-transformed values in
all further analysis. We assessed correlations among im-
mune markers using Pearson’s correlation coefficients.
Receiver operating characteristic (ROC) curve analysis
was performed on 27 immune markers to assess their
ability to classify depressed patients and non-depressed
controls. We selected the immune markers with an area
under the ROC curve (AUC) of at least 0.85 and a speci-
ficity of at least 0.85 for a stepwise discriminant analysis
(DA), as we aimed at defining a selection of a few factors
that could simultaneously classify depressed patients and
non-depressed controls. We adopted a cut-off of 0.85 to
ensure that only immune markers with good classifica-
tion ability would be included in the DA. The immune
markers chosen by a stepwise DA were further explored
in bivariate and multivariate linear regression models for
a continuous HRSD-17 score. We entered the inter-
action terms between each immune marker and the vari-
able identifying patients and controls into the regression
model. A significant interaction implies that the immune
marker is associated to the HRSD-17 score differently
among the depressed patients and the non-depressed
controls. All non-significant interactions were excluded.
Finally, we adjusted the multivariate regression model
for gender, age, CIRS-G scores and BMI.
The IBM SPSS Statistics 22 software and STATA v.12
were used for statistical analyses. All tests were two-sided,
and we deemed the results with p-values below 0.05 to be
statistically significant.
Results
Concentration of plasma immune markers in the patients
versus the controls
We found higher concentrations of 22 immune markers
(IL-1β, IL-1ra, IL-2, IL-5, IL-6, IL-7, IL-8, IL-9, IL-12,
IL-13, IL-15, IL-17, eotaxin, bFGF, G-CSF, GM-CSF,
MCP-1, MIP-1β, PDGF-BB, RANTES, TNF and VEGF)
and lower concentration of IP-10 in the patients com-
pared to the controls (Table 2). On the other hand, the
concentrations of IL-4, IL-10, IFN-γ and MIP-1α were not
significantly different between the two groups (Table 2).
Only four immune markers (IL-1β, IL-5, IL-10 and IL-15)
had concentrations below the lower detection limit in a con-
siderable portion (77, 78, 91 and 39% respectively) of the pa-
tient cases. The remaining 23 immune markers had
concentrations above the lover detection limits in 81–100%
of the patient cases. In contrast, 18 immune markers (IL-1β,
IL-1ra, IL-2, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12, IL-13, IL-15,
Table 1 Characteristics of the patient group and the non-
depressed control group
Patients, N = 64 Controls, N = 18
Mean (SD), N (%) Mean (SD), N (%) P-value
HRSD-17 23.1 (4.6) 2.7 (2.7) < 0.001a
MMSE 27.7 (1.8) 28.2 (2.1) 0.432a
Age, years 75.2 (6.3) 78.1 (4.8) 0.083a
Education, years 13.6 (3.0) 13.4 (2.8) 0.805a
BMI 23.3 (4,6) 24.2 (4.1) 0.422a









Abbreviations: CIRS-G cumulative illness rating scale for geriatric patients,
HRSD-17 Hamilton rating scale of depression, MMSE Mini mental state
examination, N number, SD standard deviation, BMI body mass index
aIndependent Samples t-test
bχ2-test.
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IL-17, bFGF, G-CSF, MIP-1α, PDGF-BB, TNF and VEGF)
had concentrations below the lower detection limit in more
than 20% of the cases in the controls (Table 2).
Gender, age, physical health, BMI, cognition and educa-
tion were not significantly different between the groups
(Table 1).
The impact of physical disorders on the immune markers
within the patient group
Within the patient group, 37 patients with reported
physical diseases affecting the immune activity had
worse but not significantly different (p = 0.074) physical
health as measured with CIRS_G (mean CIRS-G = 7.5)
compared to 27 patients without reported physical dis-
eases affecting the immune system activity (mean
CIRS-G = 5.9) (Additional file 1: Table S1). Of the 27
assessed immune markers, only the plasma concentra-
tion of IL-5, IL-8 and VEGF were significantly higher in
the patients with reported physical diseases affecting the
immune system activity (p = 0.015, 0.020 and 0.016,
respectively) compared to the patients without physical
diseases affecting the immune system activity. Because
Table 2 Descriptive statistics of the plasma immune markers
Immune markers Patients, N = 64 Controls, N = 18
Name Signalling Median (Q1, Q3), pg /ml Median (Q1, Q3), pg /ml P-value
f
IL-1β Pro-infl. 1.4 (1.1; 2.0)a 0.5 (0.3; 0.6)e < 0.001
IL-6 Pro-infl. 6.0 (4.0; 8.0) 2.0 (0.9; 2.3)e 0.001
TNF Pro-infl. 25 (14; 38) 10 (3; 13)e < 0.001
IL-12 Pro-infl. 9.0 (6.0; 14.8) 0.2 (0.0; 7.5)e 0.030
IL-17 Pro-infl. 13 (4; 27) 0.0 (0.0; 0.0)e < 0.001
IFN-γ Pro-infl. 46 (22; 77) 25 (6; 39) 0.067
PDGFBB Pro-infl. 17 (7; 37) 2.0 (0.0; 4.8)e 0.003
IL-8 Pro-infl. 10 (8; 13) 5.0 (3.8; 7.0) < 0.001
Eotaxin Pro-infl. 60 (47; 84) 30 (25; 43) 0.001
IP-10 Pro-infl. 574 (424; 732) 725 (577; 1000) 0.047
MCP-1 Pro-infl. 20 (17; 26) 12 (9; 14) < 0.001
MIP-1α Pro-infl. 3.0 (2.0; 4.0) 2.0 (0.9; 3.0)e 0.052
MIP-1β Pro-infl. 54 (46; 65) 42 (35; 52) 0.022
RANTES Pro-infl. 1116 (633; 2711) 571 (347; 850) 0.016
IL-1ra Anti-infl. 67 (42; 103) 18 (0; 29)e 0.005
IL-10 Anti-infl. 0.0 (0.0; 1.1)c 0.0 (0.0; 0.6)e 0.839
IL-2 Adaptive 5.0 (2.3; 8.0) 0.1 (0.0; 2.3)e 0.001
IL-4 Adaptive 2.0 (1.0; 2.0) 1.0 (1.8; 1.0) 0.208
IL-5 Adaptive 1.2 (1.0; 1.5)b 0.9 (0.8; 1.1)e < 0.005
IL-7 Adaptive 6.0 (4.3; 7.8) 1.3 (0.1; 2.3)e < 0.001
IL-9 Adaptive 12 (8; 15) 3.5 (0.4; 8.3)e 0.003
IL-13 Adaptive 4.5 (3.0; 8.0) 2.0 (1.3; 3.0)e 0.002
IL-15 Adaptive 2.5 (0.0; 4.8)d 0.0 (0.0; 0.0)e < 0.001
GMCSF Trophic 13 (9; 18) 6.0 (0.7; 10.0) < 0.001
GCSF Trophic 25. (16; 35) 0.0 (0.0; 12.3)e < 0.001
bFGF Trophic 26 (15; 36) 0.0 (0.0; 15.5)e 0.001
VEGF Trophic 15 (9; 23) 0.0 (0.0; 1.5)e < 0.001
Abbreviations: Anti-infl. Anti-inflammatory, bFGF basic fibroblast growth factor, G-CSF granulocyte-colony stimulating factor, GM-CSF granulocyte macrophage
colony stimulating factor, IFN interferon, IL interleukin, IP-10 interferon-inducible protein, MCP-1 monocyte chemotactic protein, MIP macrophage inflammatory
protein, ml millilitre, N number, PDGF-BB platelet derived growth factor-BB, pg picogram, Pro-infl. Pro-inflammatory, Q quartile, RANTES regulated upon activation T
cell expressed and secreted, TNF tumour necrosis factor, VEGF vascular endothelial growth factor
a The concentration values were extrapolated beyond standard range in 49 cases.
b The concentration values were extrapolated beyond standard range in 50 cases.
c The concentration values were extrapolated beyond standard range in 23 cases and the concentration values were out of range in 35 cases.
d The concentration values were extrapolated beyond standard range in three cases and the concentration value were out of range in 22 cases.
e The concentration values were out of range or extrapolated beyond standard range in more than 20% of the cases.
f Independent samples median test.
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of the similarity in concentration of immune markers be-
tween these two groups of patients, we treated the patients
as one group.
Classification of patients and controls by a panel of
plasma immune markers
According to the ROC curve analyses (Table 3), nine
markers (IL-1β, IL-1ra, IL-7, IL-8, IL-17, GM-CSF,
MCP-1, TNF and VEGF) discriminated well between the
patients and the controls as defined by the area under
the ROC curve (AUC) of at least 0.85, and with a specifi-
city of at least 0.85. The concentrations of all immune
markers correlated on a range of weakly to strongly
(data not shown).
A step-wise discriminant analysis on the nine immune
markers identified by ROC analysis suggested that the
five markers, VEGF, IL-7, MCP-1, TNF and IL-1β (Fig. 2)
are sufficient to classify the patients and the controls
without loss of discriminatory power. The five markers
correctly classify 98.4% of the patients and 83.3% of the
controls, implying a correct classification rate of 95.1%.
The association between immune markers and the
severity of symptoms characterizing MD
No significant interactions were found in bivariate linear
regression models, implying that there are no differences
between the patients and the controls regarding the
positive association between the HRSD-17 score and
each of the five immune markers. In the multivariate
linear regression model IL-7, TNF and VEGF were sig-
nificantly associated with the HRSD-17 score. After
adjusting for age, gender, CIRS-G and BMI; only TNF
and VEGF remained significantly associated with the
HRSD-17 score (Table 4). This model explained 53.3%
of the total variance of the HRSD-17 score.
Discussion
Effect size of the relationship between inflammation and MD
Our finding showing a higher concentration of a variety of
immune markers representing pro- and anti-inflammatory,
adaptive and trophic signalling indicates that several im-
mune mechanisms may be involved in MD in old psychi-
atric inpatients. Additionally, our results indicate that the
immune system may be highly activated in old psychi-
atric inpatients with MD, and this is consistent with a
meta-analysis suggesting a dose-response relationship
between inflammation and MD [14]. Further, the
meta-analysis based mainly on adult outpatients re-
ported medium effect size in the relationship between
inflammation and MD [14]. The explorative approach
of our study with a study population capable of detect-
ing only large effect sizes between inflammation and
MD, excluded reliable hypothesis testing. Therefore,
identifying a more precise effect size in the relationship
between inflammation and MD in old psychiatric inpa-
tients requires further studies. However, our sample of
old depressed inpatients is still the largest one in which
study focused on the relationship between inflamma-
tion and MD. Thus, our study may contribute to better
power calculations in the planning of future studies and
testing of our hypothesis.
Low plasma concentrations of immune markers
We found low plasma concentrations of IL-1β, IL-5,
IL-10 and IL-15 in the patients and the controls,
which is a finding in line with a previous study
Table 3 The receiver operating characteristic curve analyses of
plasma immune markers
Immune markers AUC a CI (95%) Sensitivity Specificity
IL-1β 0.97 (0.93; 1.00) 0.94 0.95
IL-1ra 0.86 (0.74; 0.99) 0.89 0.85
IL-2 0.84 (0.72; 0.96) 0.81 0.75
IL-4 0.78 (0.68; 0.87) 0.63 0.90
IL-5 0.80 (0.70; 0.90) 0.81 0.75
IL-6 0.86 (0.72; 1.00) 0.94 0.80
IL-7 0.94 (0.85; 1.00) 0.94 0.90
IL-8 0.93 (0.86; 0.99) 0.84 0.85
IL-9 0.86 (0.74; 0.98) 0.83 0.70
IL-10 0.52 (0.38; 066) 0.44 0.65
IL-12 0.84 (0.70; 0.97) 0.92 0.75
IL-13 0.81 (0.69; 0.92) 0.70 0.90
IL-15 0.81 (0.74; 0.88) 0.63 1.00
IL-17 0.89 (0.79; 1.00) 0.94 0.85
Eotaxin 0.88 (0.79; 0.97) 0.80 0.80
bFGF 0.86 (0.77; 0.96) 1.00 0.60
GCSF 0.93 (0.85; 1.00) 0.98 0.75
GMCSF 0.86 (0.78; 0.95) 0.56 1.00
IFN-γ 0.71 (0.58; 0.83) 0.59 0.80
IP-10 0.69 (0.56; 0.83) 0.02 1.00
MCP-1 0.90 (0.84; 0.97) 0.81 0.90
MIP-1α 0.72 (0.58; 0.87) 0.98 0.45
MIP-1β 0.75 (0.60; 0.89) 0.78 0.65
PDGFBB 0.83 (0.70; 0.96) 0.86 0.75
RANTES 0.71 (0.58; 0.84) 0.64 0.75
TNF 0.88 (0.80; 0.96) 0.75 0.90
VEGF 0.98 (0.95; 1.00) 0.92 0.95
Abbreviations: AUC area under curve, bFGF basic fibroblast growth factor, CI
confidence interval, G-CSF granulocyte-colony stimulating factor, GM-CSF
granulocyte macrophage colony stimulating factor, IFN interferon, IL
interleukin, IP-10 interferon-inducible protein, MCP-1 monocyte chemotactic
protein, MIP macrophage inflammatory protein, PDGF-BB platelet derived
growth factor-BB, RANTES regulated upon activation T cell expressed and
secreted, TNF tumour necrosis factor, VEGF vascular endothelial growth factor
a AUC: Area under the receiver operating characteristic (ROC) curve
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reporting low serum concentration of IL-10 in adult de-
pressed out-patients and non-depressed controls [31]. The
low concentrations make our comparisons of these four
immune markers between the two groups less reliable;
further exploration of these markers in old psychiatric in-
patients with MD may require more sensitive laboratory
methods than the multiplex analyses [32]. Furthermore,
14 immune markers had plasma concentrations below the
lower detection limit in more than 20% of the cases in the
controls. However, values out of range were given the
value 0.001 pg/ml and the concentrations were compared
using medians to limit the risk of overestimating the
differences between the groups.
High levels of trophic cytokines in the patient group
compared to the controls
The trophic cytokines bFGF, G-CSF, GM-CSF and VEGF
were higher in the patients compared to the controls.
That is the opposite of what may be expected, as the
more widely studied brain derived neurotrophic factor
(BDNF) seems to be lower in untreated patients with
MD compared to healthy controls [33]. On the other
hand, higher level of VEGF in the patients with MD
compared to the controls is a finding consistent with re-
ports in previous studies [34]. Finally, pro-inflammatory
cytokines like IL-1, TNF and INF-γ may induce
GM-CSF, and could at least explain the high concentra-
tion of GM-CSF [35].
Classification of patients and controls by a selection of
plasma immune markers
Applying step-wise DA on a large number of immune
markers implies some risk of detecting false effects and
failing to select the best subset of markers able to de-
scribe differences between the two groups. To reduce
the latter problem, we performed ROC curve analysis
prior to DA to identify the most promising markers that
could separate the patients from the controls.
Fig. 2 Plasma immune markers associated with the severity of symptoms characterizing unipolar major depression. The median concentration of
the plasma immune markers in old patients with unipolar major depression and old non-depressed controls are illustrated by the boxes. First and
third quartiles are illustrated by the error bars. Abbreviations: pg/ml, picogram/millilitre; TNF, tumour necrosis factor; VEGF, vascular endothelial
growth factor; IL, interleukin; MCP-1, monocyte chemotactic protein
Table 4 Linear regression models, immune markers associated with the Hamilton rating scale of depression
Bivariate linear reg. Models Linear regression model assessing five immune markers simultaneously with HRSD-17
Unadjusted Adjusteda
Immune markers Reg. coef. (SE) p-value Reg. coef. (SE) p-value Reg. coef. (SE) p-value
IL-1β.b 7.2 (1.1) < 0.001 3.1 (2.2) 0.157 3.7 (2.2) 0.101
IL-7.b 3.2 (0.5) < 0.001 1.7 (0.7) 0.017 1.5 (0.7) 0.059
MCP-1.b 8.9 (1.9) < 0.001 2.4 (1.9) 0.212 3.0 (2.0) 0.146
TNF.b 2.6 (0.7) < 0.001 −2.5 (1.0) 0.015 −2.5 (1.0) 0.017
VEGF.b 1.8 (0.2) < 0.001 1.2 (0.4) 0.002 1.1 (0.4) 0.005
Abbreviations: HRSD-17 Hamilton rating scale of depression, CIRS-G cumulative illness rating scale for geriatric patients, BMI body mass index, Reg regression, coef
coefficient, SE standard error, IL interleukin, MCP-1 monocyte chemotactic protein, TNF tumour necrosis factor, VEGF vascular endothelial growth factor
aAdjusted for age, gender, CIRS-G (continuous) and BMI
bLN transformed.
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Our explorative statistical analyses elucidating immune
markers that may classify old persons correctly into the
depressed and the non-depressed group suggested that
only five markers (VEGF, IL-7, MCP-1, TNF and IL-1β)
simultaneously classified about 95% of the persons cor-
rectly. To our knowledge, this has not been reported
previously. However, the analyses imply a risk for Type 1
error and were not based on prior knowledge about the
immune markers’ ability to separate depressed patients
from non-depressed controls. Therefore, the ability of
these five immune markers to separate depressed from
non-depressed should be replicated in a new population.
The association between immune markers and the
severity of symptoms characterizing MD
We found a significant association between the severity
of depression rated by the HRSD-17 and the levels of
the three immune markers VEGF, IL-7, and TNF in the
multivariate regression model. After adjusting the associ-
ations for age, gender and CIRS, only VEGF and TNF
remained significantly associated to the HRSD-17
score. In contrast to the bivariate linear regression
model, the multivariate regression model suggested a
negative association between TNF and HRSD-17
(Table 4), which is likely due to over-adjustment in
the model caused by strong correlations among the
immune markers (Additional file 2: Table S2). Our
finding deviates from that of Thomas et al. [8] who
found a correlation between the level of IL-1β and
the severity of the depression in old persons. Add-
itionally, our finding contrasts with the results of
Brambilla et al. [9], who found no correlation at all
between the severity of the depression and the levels of in-
flammatory cytokines in old persons. However, Brambilla
et al. [9] included only ten old patients with MD and con-
sequently may not have had enough statistical power to
detect putative group differences.
A small number of patients in this and previous stud-
ies, as well as differences in the study populations, may
have contributed to the conflicting results.
Limitations regarding the study groups
Limited inclusion and exclusion criteria were defined for
the controls in our study and did not ensure an optimal
match of patients and controls. However, the groups did
not differ significantly regarding gender, age, physical
health, BMI, cognition and education, and this indicates
an acceptable match between the groups. Still, we do
not know if the groups differed in health behaviours,
personality and emotional loneliness (Additional file 3:
Table S3). Nevertheless, according to Mottus et al. [36]
health behaviours such as smoking, alcohol intake and
physical activity did not significantly affect inflammation
in old. However, personality had a minor impact on
inflammation in old persons [36]. Likewise, loneliness
seems to have limited impact on inflammation in adults
[37]. Thus, potential differences in health behaviour, per-
sonality and emotional loneliness between the patients
and the controls in our study may potentially alter our re-
sults to a slight extent.
The controls were not examined in the same way as the
patients. Physical diseases were assessed by self-reporting
only; medication was not assessed, and MD was excluded
by using the HRSD-17, not by a psychiatric interview.
Consequently, we may have missed pro-inflammatory
medical conditions and we may have included controls
with MD in remission with ongoing anti-depressive medi-
cation leading to an underestimation of the differences
between the groups. However, because physical diseases
such as heart disease and cancer seem to have a small im-
pact on the levels of immune markers [38–42] compared
to MD, a possible underestimation of the difference be-
tween the groups is probably small. This is also in line
with our results where only three of 27 immune markers
had significantly higher concentrations in patients with
physical diseases affecting the immune system activity
compared to the patients without. Likewise, if we acciden-
tally included MD outpatients in remission and groups
such as controls, this would probably not have altered our
results because the levels of cytokines seem to be equal
between outpatients treated with anti-depressive medica-
tion and healthy controls [43].
Our patient group represents old MD psychiatric inpa-
tients that have not responded to medication and psy-
chotherapy as outpatients, therefore our results should
not be projected to younger adults or outpatients.
Limitations in the study design and data collections
The explorative cross-sectional design of this study excludes
reliable testing of hypotheses and determination of the tem-
porality in the associations demonstrated between immune
markers and symptoms characterizing MD. Additionally, ex-
ploring a wide range of immune markers increases the risk
of identifying false effects (Type I error) and the limited
number of participants implies that only large effects sizes
may be demonstrated (Type II error). Further, the accuracy
of the data may be affected by the self-reporting nature of
data sampling in the control group. Lastly, the plasma con-
centrations of several immune markers in the control group
were below the lower-detection level, which may also influ-
ence the accuracy of comparison between the patient group
and the controls.
Conclusion
Our results indicate that several inflammatory mecha-
nisms may be highly activated in old psychiatric inpa-
tients with MD, and indicate that immune markers
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may contribute to a more comprehensive understanding
of MD in old persons.
Additional files
Additional file 1: Table S1. Characteristics of the patients. The variables;
HRSD-17, age, BMI, CIRS-G, gender, number of drugs and current depres-
sion in weeks are compared between patients with and without physical
diseases affecting the immune system activity. (DOCX 15 kb)
Additional file 2: Table S2. Correlation among the immune markers
and the HRSD-17. Correlation among IL-1β, IL-7, MCP-1, TNF, VEGF and
the HRSD-17. (DOCX 17 kb)
Additional file 3: Table S3. Dataset supporting. Data on all
characteristics and the concentrations of all 27 immune markers of 64
patients and 18 controls. (XLSX 25 kb)
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